Lewis Karen 4
4 · Apellis Pharmaceuticals, Inc. · Filed Jan 24, 2024
Insider Transaction Report
Form 4
Lewis Karen
Chief People Officer
Transactions
- Sale
Common Stock
2024-01-23$63.69/sh−4,286$272,975→ 47,637 total
Footnotes (1)
- [F1]This is a scheduled sale from an established 10b5-1 plan.